Article Details

Incyte shares drop after FDA approves GSK's competing blood-cancer treatment

Retrieved on: 2023-09-18 12:17:49

Tags for this article:

Click the tags to see associated articles and topics

Incyte shares drop after FDA approves GSK's competing blood-cancer treatment. View article details on hiswai:

Excerpt

Ojjaara will likely put pressure on uptake of Jakafi as a first-line treatment for myelofibrosis, Truist Securities analysts wrote in a note Friday.

Article found on: www.morningstar.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up